Bailey John E. (Jack) Jr. 4
4 · G1 Therapeutics, Inc. · Filed Jan 8, 2024
Insider Transaction Report
Form 4
Bailey John E. (Jack) Jr.
Director
Transactions
- Sale
Common Stock
2024-01-03$3.12/sh−9,094$28,363→ 489,594 total - Award
Stock Options (Right to Buy)
2024-01-03+201,300→ 201,300 totalExercise: $2.97Exp: 2034-01-03→ Common Stock (201,300 underlying) - Sale
Common Stock
2024-01-03$3.12/sh−2,592$8,084→ 498,688 total - Award
Common Stock
2024-01-03+100,700→ 501,280 total
Footnotes (8)
- [F1]Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2025 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
- [F2]Each RSU represents a contingent right to receive one share of Issuer common stock.
- [F3]Represents (i) 131,130 shares of common stock; (ii) 28,750 RSUs from award granted on January 3, 2022; (iii) 80,700 RSUs from award granted on January 3, 2023; (iv) 160,000 RSUs from award granted on May 10, 2023; and (v) 100,700 RSUs from award granted on January 3, 2024.
- [F4]The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
- [F5]The price represents the weighted average price with a low of $3.08 and a high of $3.16. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]Represents (i) 134,288 shares of common stock; (ii) 23,000 RSUs from award granted on January 3, 2022; (iii) 80,700 RSUs from award granted on January 3, 2023; (iv) 160,000 RSUs from award granted on May 10, 2023; and (v) 100,700 RSUs from award granted on January 3, 2024.
- [F7]Represents (i) 145,369 shares of common stock; (ii) 23,000 RSUs from award granted on January 3, 2022; (iii) 60,525 RSUs from award granted on January 3, 2023; (iv) 160,000 RSUs from award granted on May 10, 2023; and (v) 100,700 RSUs from award granted on January 3, 2024.
- [F8]The shares underlying this option vest as to 25% of the shares on January 3, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.